• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, November 20, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Formulation Technologies Enable Mushroom Bioactive Compounds in Foods and Cosmeceuticals

by
November 17, 2026
in Agriculture, Health
Reading Time: 6 mins read
0
Formulation Technologies Enable Mushroom Bioactive Compounds in Foods and Cosmeceuticals

Formulation Technologies Enable Mushroom Bioactive Compounds in Foods and Cosmeceuticals

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A comprehensive scientific review in Food Production, Processing and Nutrition reveals that advanced formulation technologies are becoming decisive in translating fungal secondary metabolites into practical nutraceuticals, functional foods, and cosmeceuticals. While mushrooms have long held a traditional dietary role and demonstrated pharmacological potential, their raw bioactives face severe delivery barriers that prevent crude extracts from achieving predictable biological efficacy in commercial products. Fungi synthesize a rich repertoire of secondary metabolites, including polysaccharides, lanostane-type triterpenoids, phenolics, and sulfur-containing antioxidants with documented antioxidant, anti-inflammatory, and immunomodulatory properties. However, unformulated fungal compounds frequently suffer from poor aqueous solubility, physical instability under light and heat, and limited gastrointestinal bioavailability. Moving from laboratory bioactivity to market-ready products requires bridging pharmacology with formulation science through specialized carrier systems such as nanoencapsulation, lipid nanocarriers, and biopolymer microcapsules tailored to fungal metabolite profiles.

Natural production bottlenecks represent the initial obstacle to commercializing mushroom-derived bioactives, as secondary metabolites occur in low, variable concentrations within fungal biomass. To address these yield constraints without compromising biochemical integrity, researchers are deploying industrial fermentation alongside metabolic engineering, synthetic biology, and CRISPR-based gene editing. Multi-omics analyses encompassing genomic, transcriptomic, and metabolomic profiling decode the metabolic plasticity through which fungi respond to environmental stresses, facilitating the deliberate up-regulation of high-value pathways. These platforms improve production yields and accelerate the discovery of novel bioactive molecules. However, the review emphasizes that optimizing biological synthesis resolves only part of the translational pipeline. Downstream formulation engineering must operate synchronously with upstream cultivation to convert biologically potent fungal fractions into stable, reproducible ingredients compatible with industrial manufacturing processes.

Within fungal metabolic repertoires, specific chemical classes exhibit distinct physiological mechanisms and corresponding delivery demands across nutraceutical and cosmeceutical sectors. Polysaccharides, particularly cell-wall beta-glucans, represent the most industrially explored mushroom fractions and are recognized for immunomodulatory and prebiotic properties. Concurrently, low-molecular-weight sulfur-containing antioxidants, led by the histidine-derived amino acid ergothioneine, demonstrate remarkable cytoprotective capabilities by concentrating selectively in cellular mitochondria and nuclei through OCTN1 transporter-mediated uptake, directly mitigating oxidative damage. Triterpenoids, including lanostane derivatives from Ganoderma species, exhibit potent anti-inflammatory and anticancer mechanisms in preclinical evaluations by suppressing cellular proliferation and inhibiting critical signaling cascades such as NF-κB and JAK-STAT3. Additionally, fungal phenolic profiles, comprising hydroxybenzoic acids, hydroxycinnamic acids, and flavonoids, contribute broad-spectrum free-radical scavenging. Despite these established bioactivities, the extreme hydrophobicity of triterpenoids and the oxidative susceptibility of phenolics necessitate specialized protective carrier architectures.

Standardization remains an exceptionally rigorous hurdle in mushroom product development due to pronounced chemical heterogeneity driven by environmental and cultivation parameters. Investigations cited in the review show that wood-culture and bag-culture methods for identical shiitake species yield marked differences in total terpenoid and phenolic content, directly altering measured antioxidant and hypoglycemic activities. Similarly, wild collections of Inonotus obliquus sclerotia exhibit substantial regional divergence in betulinic acid and inotodiol levels alongside variable cytotoxic effects. In functional food production, substrate interactions strongly govern metabolite output; cultivating Pleurotus and Agaricus species on agricultural by-products such as wheat straw, wine pulp, or olive residues induces notable shifts in lovastatin and ergothioneine synthesis. Consequently, rigorous standardization protocols utilizing high-performance liquid chromatography and mass spectrometry fingerprinting are indispensable for ensuring batch reproducibility.

To overcome the physical and chemical vulnerabilities of mushroom secondary metabolites, biopolymer microencapsulation has emerged as a practical, scalable delivery strategy for food and nutraceutical applications. Typically produced through spray drying, freeze drying, coacervation, or extrusion, microencapsulation coats sensitive fungal extracts within food-grade wall materials such as maltodextrin, gum arabic, alginate, and whey protein. Although biopolymer systems report moderate encapsulation efficiencies between 50 and 80 percent, their high technological readiness offers major processing advantages. For example, during thermal baking, alginate-based microencapsulation maintains polyphenol retention at nearly 90 percent, preventing the severe losses observed in unencapsulated forms, which retain only 42 to 60 percent. Furthermore, microencapsulating phenolics within blended matrices of maltodextrin, nutriose, and alginate restricts degradation to between 3 and 12 percent across twelve months of storage, ensuring long-term stability without synthetic additives.

Where biopolymer microcapsules excel in industrial scalability, nanoscale delivery architectures provide superior capabilities in solubilizing highly hydrophobic compounds and elevating cellular bioavailability. Polymeric nanoparticles, nanocapsules, and lipid-based nanocarriers such as solid lipid nanoparticles and nanostructured lipid carriers frequently achieve encapsulation efficiencies exceeding 70 to 90 percent. Nanostructured lipid carriers are particularly advantageous for hydrophobic triterpenoids because their blend of solid and liquid lipids forms an imperfect crystalline matrix that enhances loading capacity while preventing active expulsion. Nanoscale encapsulation has demonstrated clear biological advantages; loading Lentinula edodes extracts onto zein–chitosan nanoemulsion carriers significantly augments antioxidant, anti-inflammatory, and anticancer activities compared with free extracts. Moreover, engineered zein–alginate–chitosan nanoparticle complexes have been documented to elevate phenolic bioavailability by more than 65 percent, achieving an absorption improvement of at least 50 percent relative to unformulated compounds.

A pivotal physiological challenge highlighted throughout the review concerns the limited oral bioavailability and low gastrointestinal stability of fungal bioactives. To overcome gastrointestinal barriers, researchers are developing smart, pH-responsive hydrogels using biopolymers such as alginate, chitosan, pectin, and fucoidan. These polysaccharide matrices resist gastric acid erosion through restricted swelling in low-pH environments but dissolve rapidly upon encountering neutral to alkaline intestinal fluids. Experimental evaluations confirm that calcium–alginate bead networks loaded with nanoparticles release less than 5 percent of their payload under simulated gastric conditions, while delivering virtually complete release within simulated intestinal fluid. Such targeted delivery systems ensure that immunomodulatory beta-glucans reach the lower gastrointestinal tract intact. Nevertheless, current pharmacokinetic evidence remains predominantly restricted to in vitro and preclinical animal models.

Beyond preserving chemical integrity and elevating physiological bioavailability, formulation design determines sensory acceptance and physical functionality in enriched foods. Incorporating raw fungal powders into foods such as breads, cookies, pasta, dairy matrices, and beverages frequently introduces unpalatable sensory profiles characterized by earthy notes and intense umami flavors. Encapsulation techniques provide an effective solution; studies reveal that microencapsulating mushroom extracts within carbohydrate or protein walls successfully masks over 90 percent of objectionable earthy and umami flavors in functional health beverages without compromising bioactive release. Technologically, mushroom powders and derived polysaccharides function as natural emulsifiers, stabilizers, and water-binding agents. For instance, incorporating microencapsulated Agaricus bisporus extracts into yogurt matrices substantially bolsters antioxidant capacity across prolonged storage periods while preserving sensory texture and product stability, demonstrating the feasibility of integrating fungal bioactives into complex food systems.

In cosmeceutical and nutricosmetic applications, fungal secondary metabolites are increasingly formulated into topical creams, gels, and oral photoprotective supplements targeting skin aging mechanisms. Cutaneous aging is driven by ultraviolet-induced reactive oxygen species, chronic inflammation, and enzymatic breakdown of the dermal matrix. Fungal phenolics, triterpenoids, and beta-glucans counteract these pathways by scavenging free radicals and inhibiting matrix-degrading enzymes, including elastase, collagenase, hyaluronidase, and tyrosinase. For instance, Lentinus squarrosulus mycelium, containing a high beta-glucan fraction of 64 percent, demonstrates pronounced inhibitory effects against collagenase, elastase, and tyrosinase, supporting anti-aging formulations. Furthermore, advanced carrier systems preserve 85 to 100 percent of sensitive fungal components like phenolic acids and ergosterol within topical creams. In nutricosmetics, oral Pleurotus extract ingestion provides measurable photoprotection, reducing UVB-induced transepidermal water loss and epidermal thickening, confirming that fungal metabolites can support skin barrier function through topical and oral delivery routes.

Commercialization of mushroom-based formulations faces intricate regulatory constraints, quality control requirements, and safety assessments that vary substantially between jurisdictions. In the European Union, mycelium-derived biomass is categorized as a Novel Food requiring toxicological documentation and exposure modeling even if the mushroom fruiting body has a history of traditional human consumption. Health claims evaluated under the European Food Safety Authority require verified batch consistency, chemical fingerprinting, and evidence of causal physiological effects from controlled human clinical trials, whereas the United States framework under DSHEA permits structure-function claims with greater regulatory flexibility. Compounding these administrative differences are safety concerns in commercial markets, including species misidentification, discrepancies in declared beta-glucan content, and heavy metal contamination. Furthermore, while mushroom polysaccharides are generally safe, high oral doses can cause gastrointestinal disturbances, necessitating rigorous dose-response validation and species authentication across all production chains.

To bridge the persistent translational divide between promising laboratory bioactivity and commercially viable products, the authors propose a systematic species-oriented evaluation framework based on measurable technological criteria. Rather than selecting mushroom species purely for isolated bioactivity, formulation scientists must evaluate metabolite stability across cultivation batches, availability of analytical chromatographic fingerprinting, sensory impact, processing tolerance, and regulatory familiarity. Under this formulation-driven paradigm, Ganoderma, Cordyceps, and Hericium erinaceus emerge as leading candidates for nutraceutical capsules and liquid extracts, combining dense triterpenoid or neuroactive profiles with established safety histories. Conversely, Lentinula, Pleurotus, and Agaricus species are optimal for functional food enrichment, offering mild sensory footprints, water-holding capacity, and widespread culinary acceptance. For topical cosmeceuticals, metabolite-dense taxa such as Ganoderma, Lentinula, and Pleurotus provide verified skin-protective bioactives. Ultimately, closing the translational gap will require transitioning from small-scale laboratory trials toward rigorous human clinical trials and validated pilot-scale manufacturing.

Subject of Research: Formulation and delivery strategies for mushroom-derived secondary metabolites in commercial health products

Article Title: Bioactive secondary metabolites of mushrooms and their potential applications in nutraceuticals, functional foods and cosmeceuticals with selected formulation approaches

Article References: Krupodorova, T., Gürgen, A., Sevindik, M., Eraslan, E. C., Bal, C., & Akata, I. (2026). Bioactive secondary metabolites of mushrooms and their potential applications in nutraceuticals, functional foods and cosmeceuticals with selected formulation approaches. Food Production, Processing and Nutrition, 8(1), Article 43. https://doi.org/10.1186/s43014-026-00393-w

Image Credits: AI Generated

DOI: 10.1186/s43014-026-00393-w

Keywords: mushroom secondary metabolites, bioactive compounds, nanoencapsulation, microencapsulation, functional foods, nutraceuticals, cosmeceuticals, beta-glucans, ergothioneine, triterpenoids, phenolic compounds, solid lipid nanoparticles, spray drying, pH-responsive hydrogels, Lentinula edodes, Ganoderma, Agaricus bisporus, Novel Food regulations

News Source: Alan Morgan. (November 17, 2026). Formulation Technologies Enable Mushroom Bioactive Compounds in Foods and Cosmeceuticals. Scienmag.

Tags: Agaricus bisporusbeta-glucansbioactive compoundscosmeceuticalsergothioneinefunctional foodsGanodermaLentinula edodesmicroencapsulationmushroom secondary metabolitesnanoencapsulationNovel Food regulationsnutraceuticalspH-responsive hydrogelsphenolic compoundssolid lipid nanoparticlesspray-dryingtriterpenoids
Share12Tweet7Share2ShareShareShare1

Related Posts

Brivaracetam Shows Antiseizure Efficacy Across Genetic Generalized and Encephalopathic Epilepsies

Brivaracetam Shows Antiseizure Efficacy Across Genetic Generalized and Encephalopathic Epilepsies

November 20, 2026
B4GALT4 Drives Lung Adenocarcinoma Progression Through the Glycolysis and Lactylation Axis

B4GALT4 Drives Lung Adenocarcinoma Progression Through the Glycolysis and Lactylation Axis

November 20, 2026

Remote Medical Education Maintained Standardized Test Scores Despite Shifting Course Grades

November 20, 2026

ChatGPT-4 Leads Dental Implantology Multiple-Choice Tests While Gemini Excels in Open Questions

November 20, 2026

POPULAR NEWS

  • Hybrid PET-MRI Motion Correction Enables High-Resolution Cardiac Disease Quantification

    Hybrid PET-MRI Motion Correction Enables High-Resolution Cardiac Disease Quantification

    29 shares
    Share 12 Tweet 7
  • Microbiota Shifts Interact With Host Methylation and TP53 Mutations in Gastric Cancer

    29 shares
    Share 12 Tweet 7
  • Cardiac Imaging Links Heart Markers to Quality of Life in DMD Carriers

    29 shares
    Share 12 Tweet 7
  • Study Links 18p Chromosomal Deletions to Reproductive and Endocrine Anomalies

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Brivaracetam Shows Antiseizure Efficacy Across Genetic Generalized and Encephalopathic Epilepsies

B4GALT4 Drives Lung Adenocarcinoma Progression Through the Glycolysis and Lactylation Axis

Remote Medical Education Maintained Standardized Test Scores Despite Shifting Course Grades

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 89 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.